Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by BioHealth Innovation, Inc. (BHI), BioHealth Innovation, and Inc. (BHI). All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BioHealth Innovation, Inc. (BHI), BioHealth Innovation, and Inc. (BHI) or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

BioHealth at a Crossroads: Alex Philippidis on Policy Shifts, Investment Trends, and What’s Ahead

34:40
 
Share
 

Manage episode 479395833 series 1551347
Content provided by BioHealth Innovation, Inc. (BHI), BioHealth Innovation, and Inc. (BHI). All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BioHealth Innovation, Inc. (BHI), BioHealth Innovation, and Inc. (BHI) or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

In this timely episode of BioTalk, returning guest Alex Philippidis, Senior Business Editor at Genetic Engineering & Biotechnology News, joins host Rich Bendis to explore how sweeping changes in U.S. regulatory policy, workforce dynamics, and economic pressures are affecting the biotech industry in real time.

Alex breaks down the potential consequences of FDA workforce cuts, particularly for small and mid-sized biotechs that depend on regulatory guidance, and offers perspective on how HHS and NIH budget proposals could reshape the national innovation infrastructure. The conversation covers everything from the impact of tariffs on manufacturing and supply chains to the slowing pace of M&A activity and venture capital investment trends. Alex also shares his insights on IPO strategy shifts, and whether the current biotech environment is poised for a rebound—or a broader realignment with global competitors. This is a must-listen episode for anyone navigating the uncertain waters of biotech in 2025.

Editing and post-production work for this episode was provided by The Podcast Consultant.

Alex Philippidis is the Senior Business Editor at Genetic Engineering & Biotechnology News (GEN). Specializing in biopharma business news and industry issues, Alex joined GEN in 2011 after covering research institutes at GenomeWeb and editing the BioRegion News newsletter. With over 20 years of experience in journalism, Alex has reported on various topics for newspapers and has been featured in major media outlets such as the New York Times and the BBC.

  continue reading

175 episodes

Artwork
iconShare
 
Manage episode 479395833 series 1551347
Content provided by BioHealth Innovation, Inc. (BHI), BioHealth Innovation, and Inc. (BHI). All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BioHealth Innovation, Inc. (BHI), BioHealth Innovation, and Inc. (BHI) or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

In this timely episode of BioTalk, returning guest Alex Philippidis, Senior Business Editor at Genetic Engineering & Biotechnology News, joins host Rich Bendis to explore how sweeping changes in U.S. regulatory policy, workforce dynamics, and economic pressures are affecting the biotech industry in real time.

Alex breaks down the potential consequences of FDA workforce cuts, particularly for small and mid-sized biotechs that depend on regulatory guidance, and offers perspective on how HHS and NIH budget proposals could reshape the national innovation infrastructure. The conversation covers everything from the impact of tariffs on manufacturing and supply chains to the slowing pace of M&A activity and venture capital investment trends. Alex also shares his insights on IPO strategy shifts, and whether the current biotech environment is poised for a rebound—or a broader realignment with global competitors. This is a must-listen episode for anyone navigating the uncertain waters of biotech in 2025.

Editing and post-production work for this episode was provided by The Podcast Consultant.

Alex Philippidis is the Senior Business Editor at Genetic Engineering & Biotechnology News (GEN). Specializing in biopharma business news and industry issues, Alex joined GEN in 2011 after covering research institutes at GenomeWeb and editing the BioRegion News newsletter. With over 20 years of experience in journalism, Alex has reported on various topics for newspapers and has been featured in major media outlets such as the New York Times and the BBC.

  continue reading

175 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play